Central Nervous System (CNS) Therapeutic Market Report

Central Nervous System (CNS) Therapeutic Market Analysis By Disease (Neurovascular, Trauma, Mental Health, Degenerative Disorder [Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis], Infections, Cancer), & Segment Forecasts, 2016 - 2025

Published: July 2017  |  100 Pages  |  Format: PDF  |  Report ID: GVR-1-68038-516-8

Industry Insights

The global Central Nervous System (CNS) therapeutic market size was worth USD 77.2 billion in 2016 and is anticipated to grow at a CAGR of 5.9% during the forecast period. Advancements in diagnostics, therapeutics, and drug discovery techniques are primarily driving the growth of the market. Moreover, rising demand for effective therapeutic options are motivating major pharmaceutical companies to invest on R&D for the same, thus creating future growth opportunities.

In addition, growing geriatric population prone to various CNS diseases including Alzheimer’s and schizophrenia is expected to fuel the growth. Furthermore, the number of patients is expected to increase with increasing prevalence of CNS diseases associated with sedentary lifestyle and chronic mental disorders.

India CNS therapeutics market, by disease (USD Millions)

India CNS therapeutics market

Increasing awareness regarding mental health, social acceptance of mentally ill patients, and increasing access to advanced healthcare options are some of the principal factors expected to drive market growth. On the other hand, stringent and lengthy drug approval procedures and high prices of advanced treatments are expected to impede market growth during the forecast period.

Mental health and degenerative disorders segments are major contributors to escalating demand for the global CNS therapeutics. Technical advancement in neurological imaging, which helps in early diagnosis, is a key factor fueling growth.

Organizations such as the WHO as well as American Association of Neurological Surgeons conduct various conferences and seminars to increase awareness about mental disorders and their treatments. These organizations have also helped create communities in which patients can interact with each other and have a holistic approach toward healing, thus driving growth of the CNS therapeutics market.

Segment Insights

Mental health segment dominated the market in 2016 and is expected to continue its dominance throughout the forecast period. Increasing number of patients with mental disorders, extensive R&D, rising number of rehabilitation facilities, and the introduction of novel treatment procedures are prime factors propelling growth. R&D and the introduction of novel and advanced solutions for neurological imaging are spurring growth of the neurovascular diseases segment.

Global mental health therapeutics market, by type (%)

Global mental health therapeutics market

Cancer is expected to emerge as the fastest growing segment. This is mainly attributed to increasing mortality due to cancer and rising need for effective treatment. Companies such as Teva Pharmaceuticals and Eli Lilly and Company are focusing on manufacturing drugs that can help reduce pain associated with CNS cancers.

Neurovascular diseases & mental health segments are gaining pace due to increasing awareness and social acceptance of patients. An increasing number of rehabilitation centers along with campaigns to increase awareness and assist mental patients to adjust in society, has led to increase in the number of patients seeking treatment for mental conditions. The progress of each segment depends on the availability of skilled professionals, hospitalization facilities, and therapy with effective counseling. In recent years, there has been increased number of community hospitals with affordable treatments.

Regional Insights

North America dominated the market by capturing the largest share in 2016. This can be attributed to factors such as rising number of reported cases of depression & anxiety and high adoption of advanced therapeutics. In addition, awareness campaigns and conferences about diagnosis & treatment of CNS diseases, including mental diseases, organized by leading pharma companies and/or rehabilitation centers are expected to increase the number of patients opting for early diagnosis.

Asia Pacific is expected to exhibit highest growth rate due to high prevalence of neurodegenerative diseases, rapidly increasing awareness regarding mental health, and improving healthcare facilities. Countries such as India and China have several nongovernment organizations that offer affordable treatments to people with Alzheimer’s and Parkinson’s disease.

Middle East and Africa is expected to experience lucrative growth with increasing access to advanced therapeutic options owing to initiatives by United Nations Programme on HIV/AIDS (UNAIDS) and other nongovernmental organizations for the treatment of NeuroAIDS which affects more that 11 million people in sub-Saharan Africa .

Competitive Market Share Insights

Companies currently dominating the market are Pfizer, Inc.; Biogen, Inc.; Johnson & Johnson Services, Inc.; Eli Lilly and Company; Otsuka America Pharmaceutical, Inc.; Merck & Co., Inc.; AstraZeneca; Novartis AG; Teva Pharmaceutical Industries Ltd.; and Shire Plc. These players are investing heavily on R&D to create a strong pipeline of drugs aimed at delivering improved patient care at low costs.

Majority of companies adopt strategies such as regional expansion, enhancement of product portfolio, and development of advanced diagnostic methods to increase success rate of treatment.

Report Scope

Attribute

Details

Base year for estimation

2016

Actual estimates/Historical data

2014 - 2015

Forecast period

2017 - 2025

Market representation                                                

Revenue in USD Million and CAGR from 2016 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Country scope

U.S., Canada, U.K., Germany, India, China, Brazil, Mexico, South Africa.

Report coverage             

Revenue forecast, company share, competitive landscape, growth factors, and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels as well as provides an analysis on the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global CNS therapeutics market on the basis of disease and regions:

  • Disease Outlook (Revenue, USD Million, 2014 - 2025)

    • Neurovascular Disease

    • Trauma

    • Mental Health

      • Anxiety Disorders

      • Mood Disorders

      • Substance Abuse Disorders

      • Others (Insomnia, Binge Eating Disorder, Personality Disorders)

    • Degenerative

      • Alzheimer's Disease

      • Parkinson’s disease

      • Multiple Sclerosis

      • Others

    • Infections

    • Cancer 

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • UK

      • Germany

    • Asia Pacific

      • Japan

      • India

    • Latin America

      • Brazil

      • Mexico

    • MEA

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $4,950
Multi User - $7,950
Enterprise User - $9,950

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA